Imperial College London

ProfessorPatrickSerruys

Faculty of MedicineNational Heart & Lung Institute

Visiting Professor
 
 
 
//

Contact

 

p.serruys

 
 
//

Location

 

c/o Prof Kim FoxGuy Scadding BuildingRoyal Brompton Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Khattab:2008:10.4244/eijv3i5a102,
author = {Khattab, AA and Richardt, G and Verin, V and Kelbaek, H and Macaya, C and Berland, J and Miquel-Hebert, K and Dorange, C and Serruys, PW},
doi = {10.4244/eijv3i5a102},
journal = {EuroIntervention},
pages = {566--573},
title = {Differentiated analysis of an everolimus-eluting stent and a paclitaxel-eluting stent among higher risk subgroups for restenosis: results from the SPIRIT II trial.},
url = {http://dx.doi.org/10.4244/eijv3i5a102},
volume = {3},
year = {2008}
}

RIS format (EndNote, RefMan)

TY  - JOUR
AB - AIMS: Restenosis is higher among certain subpopulations when subjected to percutaneous coronary interventions even when using drug-eluting stents. The randomised SPIRIT II trial demonstrated the superiority of the XIENCE V Everolimus Eluting Coronary Stent System over the TAXUS Paclitaxel-Eluting Stent System in terms of in-stent late loss at six months among 300 patients treated for de novo native coronary artery lesions. METHODS AND RESULTS: In this post-hoc analysis of SPIRIT II we focused on six-month angiographic outcomes of diabetic patients (n=69), left anterior descending arteries (n=149), long lesions >20 mm (n=43), small vessels <3.0 mm (n=209) and type B2 and C lesions (n=233). In-stent late loss was consistently less among all subgroups when treated by everolimus-eluting stents compared to paclitaxel-eluting stents: diabetics 0.15+/-0.26 mm versus 0.39+/-0.34 mm, p=0.006; LAD 0.12+/-0.23 mm versus 0.44+/-0.37 mm, p<0.001; long lesions 0.13+/-0.26 mm versus 0.43+/-0.46 mm, p=0.070; small vessels 0.17+/-0.28 mm versus 0.37+/-0.39 mm, p<0.001; B2/C lesions 0.12+/-0.31 mm versus 0.36+/-0.36 mm, p<0.001. CONCLUSION: The everolimus-eluting stent remained superior in terms of in-stent late loss in a variety of higher risk populations for restenosis compared to the paclitaxel-eluting stent. These analyses were consistent with the in-stent late loss results of the overall SPIRIT II trial population.
AU - Khattab,AA
AU - Richardt,G
AU - Verin,V
AU - Kelbaek,H
AU - Macaya,C
AU - Berland,J
AU - Miquel-Hebert,K
AU - Dorange,C
AU - Serruys,PW
DO - 10.4244/eijv3i5a102
EP - 573
PY - 2008///
SN - 1774-024X
SP - 566
TI - Differentiated analysis of an everolimus-eluting stent and a paclitaxel-eluting stent among higher risk subgroups for restenosis: results from the SPIRIT II trial.
T2 - EuroIntervention
UR - http://dx.doi.org/10.4244/eijv3i5a102
UR - https://www.ncbi.nlm.nih.gov/pubmed/19608482
VL - 3
ER -